Skip to content
Screener

Innoviva, Inc. INVA Debt-to-equity

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Merck & Co. logo
Merck & Co.MRK
1.4×+0.6×
AbbVie logo
AbbVieABBV
46.6×+38.6×
Insmed logo
InsmedINSM
0.8×+0.3×
Savara logo
SavaraSVRA
0.2×0.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
0.0×

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Current ratio16×+13.4×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235

FAQ

What is Innoviva, Inc.'s debt-to-equity?
Innoviva, Inc. (INVA) reported debt-to-equity of 0.2× in Q2 2026.
What is the long-term trend for Innoviva, Inc.'s debt-to-equity?
Over 4 years (2020 to 2025), Innoviva, Inc.'s debt-to-equity has grown at a -24.7% compound annual growth rate (CAGR), from 0.7× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Innoviva, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude